Targeting the Ccl6/Ccr2 axis may attenuate fibrotic progression and offers potential therapeutic insights for preventing the transition from AKI to CKD, a possibility that warrants further validation through future functional experiments. This evidence concerns the gene CCR2 and acute kidney injury.